JDRF and ViaCyte share a
continuing commitment to realizing the potential of beta cell replacement strategies to deliver insulin independence without
immune suppression for people living with type 1 diabetes, and ultimately, at JDRF we hope this will move us forward in fulfilling our vision of a world without type 1 diabetes.»